Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Carr

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
The Lancet. Rheumatology|May 11, 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trialCarl S Goodyear, Amit Patel, Eleanor Barnes, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|April 28, 2023
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerMary Y Wu, Scott T C Shepherd, Annika Fendler, et al.
Cancer Cell|April 12, 2022
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cell Reports. Medicine|October 14, 2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|December 30, 2021
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
The Lancet. Rheumatology|May 11, 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trialCarl S Goodyear, Amit Patel, Eleanor Barnes, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|April 28, 2023
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerMary Y Wu, Scott T C Shepherd, Annika Fendler, et al.
Cancer Cell|April 12, 2022
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cell Reports. Medicine|October 14, 2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|December 30, 2021
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Pageof 6